Variant:
rs7294 at chr16:31102321 in PRSS53, VKORC1 (VIP)

Alleles (on + chromosomal strand)
C > T
Alternate Names:
VKORC1:3730G>A, VKORC1:G9041A, c.*134G>A, c.*237G>A, g.31042321C>T, g.8956G>A
Haplotypes
This variant is used to determine: VKORC1*3, VKORC1 H1, VKORC1 H2, VKORC1 H3, VKORC1 H4, VKORC1 H5, VKORC1 H6, VKORC1 H7, VKORC1 H8, VKORC1 H9

Clinical Annotations

To see the clinical annotation for this variant please register or sign in.

Variant Annotations

PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are 5 annotations for this variant. Register or sign in to see them.

VIP Variant in VKORC1

Note: The VKORC1 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand, therefore the alleles within our variant annotations and haplotypes may differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.


G9041A, or 3730 G>A, is a SNP in the 3'UTR of VKORC1, and it may be associated with a higher warfarin dose [Articles:15358623, 16676068]. It is generally not found in the same haplotypes as G3673A or C6484T. Below is a table of the frequency of the A allele at postion 9041 in different populations, and also the number of patients in the study and the PMID number for the study.

PopulationN Allele Frequency of "A" PMID
Japanese 938%[Article:17049586]
Swedish 38 38% [Article:17048007]
Japanese 9 9% [Article:17031720]
Swedish (anticoagulated) 39 39% [Article:16879214]
Swedish (healthy) 37 37% [Article:16879214]
Slovenian 36 36% [Article:16676068]
Caucasian (anticoagulated) 36 36 [Article:16611750]
Florida VA hospital 39 39% [Article:16580898]
African Americans 52 52% [Article:16424822]
Caucasians 37 37% [Article:16424822]
Japanese 17 17% [Article:16424822]
Germans 38 38% [Article:16270629]
Swedish 39 39% [Article:15883587]
Italian 35 35% [Article:15358623]
Japanese 9 9% [Article:16432637]
Key Publications:
Drugs / Other Molecules
Diseases Atrial Fibrillation Coagulation Protein Disorders Hemorrhage Vascular Diseases
Phenotype Datasets WUSTL warfarin dosing data, group A

Appendix

gp position chr16:31009822(hg18)

Connected Drugs

Connected Diseases

Publications related to rs7294 at chr16:31102321: 12

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association of warfarin dose with genes involved in its action and metabolism. Human genetics. 2007. Wadelius Mia, et al. [Article:17048007@PubMed]
Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thrombosis research. 2007. Kimura Rina, et al. [Article:17049586@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clinical pharmacology and therapeutics. 2006. Aquilante Christina L, et al. [Article:16580898@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. Journal of human genetics. 2006. Mushiroda Taisei, et al. [Article:16432637@PubMed]
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. Journal of medical genetics. 2006. Li T, et al. [Article:16611750@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records. Journal of thrombosis and haemostasis : JTH. 2006. Osman A, et al. [Article:16879214@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatric cardiology. 2006. Kosaki K, et al. [Article:17031720@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenetics and genomics. 2006. Takahashi Harumi, et al. [Article:16424822@PubMed]
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thrombosis and haemostasis. 2006. Herman Darja, et al. [Article:16676068@PubMed]
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005. D'Andrea Giovanna, et al. [Article:15358623@PubMed]
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The pharmacogenomics journal. 2005. Wadelius M, et al. [Article:15883587@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thrombosis and haemostasis. 2005. Geisen Christof, et al. [Article:16270629@PubMed]

Cross-References

UCSC Golden Path:
chr16:31102321
dbSNP:
rs7294
ALFRED:
SI549694L
HapMap:
rs7294
Seattle SNP:
VKORC1-009041

Platform Availability

  • Affymetrix
  • Illumina

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.